SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays

BACKGROUND: Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about the efficacy of antibody-based COVID-19 therapies. Therefore, in this study the in-vitro neutralization capacity against SARS-CoV-2 variant B.1 and the Omicron subvariants BA.1, BA.2 and BA.5 of sera from conva...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidel, Alina, Hoffmann, Simone, Jahrsdörfer, Bernd, Körper, Sixten, Ludwig, Carolin, Vieweg, Christiane, Albers, Dan, von Maltitz, Pascal, Müller, Rebecca, Lotfi, Ramin, Wuchter, Patrick, Klüter, Harald, Kirchhoff, Frank, Schmidt, Michael, Münch, Jan, Schrezenmeier, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166809/
https://www.ncbi.nlm.nih.gov/pubmed/37180152
http://dx.doi.org/10.3389/fimmu.2023.1170759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166809/
https://www.ncbi.nlm.nih.gov/pubmed/37180152
http://dx.doi.org/10.3389/fimmu.2023.1170759

Ejemplares similares